Powered by: Motilal Oswal

News

Concord Biotech makes a healthy debut on the exchange; shares close 27% premium over the issue price Ahmedabad-based Concord Biotech Limited a biotechnology company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022 makes a strong debut on the exchanges to close over XX% premium. The scrip listed at Rs 900.05 per share on BSE & NSE, at a premium of 21.46%. The company's share price closed at Rs 941.85 per share on the BSE, a 27.11% premi...
Concord Biotech makes a healthy debut on the exchange; shares close 27% premium over the issue price
Concord Biotech makes a healthy debut on the exchange; shares close 27% premium over the issue price
Source: PR Agency
18/08/2023 5:53:35 PM
Concord Biotech lists with 21% premium on the BSE Concord Biotech has debuted at Rs 900.05 on the BSE, up by 159.05 points or 21.46% from its issue price of Rs 741. The scrip is currently trading at Rs 937.00, up by 196.00 points or 26.45% from its issue price. It has touched a high and low of Rs 987.05 and Rs 900.00 respectively. So far 12.88 lakh shares were traded on the counter. The offering, which was open for subscription between August 4, 2023 and August 8, 2023 was subscribed 24.87 times. The issue price was fixed at Rs 741 per...
Concord Biotech lists with 21% premium on the BSE
Concord Biotech lists with 21% premium on the BSE
Source: Accord Fintech
18/08/2023 12:49:50 PM
India`s Concord Biotech up 23% in debut, valuing it at over $1 billion Shares of Indian biopharma company Concord Biotech climbed as much as 23.7% in their market debut on Friday, valuing it at 95.92 billion rupees ($1.15 billion). The company, which makes active pharmaceutical ingredients, the key biologically active elements in a drug, opened at 900.05 rupees compared with its initial public offer (IPO) price of 741 rupees. Indian benchmark indexes, the Nifty 50 and the S&P BSE Sensex, were down 0.5% each as of 10:02 a.m. IST. ($1 = 83.0800 Indian...
India`s Concord Biotech up 23% in debut, valuing it at over $1 billion
India`s Concord Biotech up 23% in debut, valuing it at over $1 billion
Source: Reuters
18/08/2023 10:19:57 AM
Concord Biotech IPO subscribed 2.72 times on Day 2 Initial public offering (IPO) of Ahmedabad-based Concord Biotech Limited a biotechnology company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022 was subscribed 2.72 times on the second day of bidding.   The issue received bids of 3,97,88,140 shares against the offered 1,46,50,957 equity shares, at a price band of ?705-741, according to...
Concord Biotech IPO subscribed 2.72 times on Day 2
Concord Biotech IPO subscribed 2.72 times on Day 2
Source: PR Agency
8/08/2023 11:25:48 AM
IPO Note : Concern Biotech Limited - LKP Securities Ltd Company Overview Concord Biotech Limited (“Concord”) is one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022, supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Concord with close to 130 DMF filings has a 20% market share globally in its top selling APIs including mupirocin, sirolimus, tacro...
IPO Note : Concern Biotech Limited - LKP Securities Ltd
IPO Note : Concern Biotech Limited - LKP Securities Ltd
Source: LKP Securities Ltd
5/08/2023 10:40:10 AM
IPO Note : Concord Biotech Ltd By Motilal Oswal Financial Services Ltd Leading manufacturer of fermentation based APIs: Concord Biotech (CBL) is one of the leading global manufacturers of select fermentationbased APIs (F-APIs) across immunosuppressants and oncology with market share of >20% by volume in 2022. It is present across the fermentation value chain, and supplies to >70 countries including regulated markets, such as US, Europe and Japan, and India. As of FY23, CBL had 23 APIs (~89% of revenue), which it aims to increase further especially in anti-...
IPO Note : Concord Biotech Ltd By Motilal Oswal Financial Services Ltd
IPO Note : Concord Biotech Ltd By Motilal Oswal Financial Services Ltd
Source: Motilal Oswal Financial Services Ltd
4/08/2023 10:23:48 AM
Concord Biotech to come out with Rs 1,550 crore IPO on August 4 Concord Biotech is coming out with an initial public offering (IPO) to raise around Rs 1,550 crore. It has fixed a price band of Rs 705-741 per share. The issue will open on August 4, 2023 and will close on August 8, 2023. The equity shares are proposed to be listed on both the bourses, BSE and NSE. The IPO is entirely an offer-for-sale (OFS) of 2.09 crore equity shares by Helix Investment Holdings, which is backed by private equity firm Quadria Capital. Kotak Mahindra Capital Company, Cit...
Concord Biotech to come out with Rs 1,550 crore IPO on August 4
Concord Biotech to come out with Rs 1,550 crore IPO on August 4
Source: Accord Fintech
31/07/2023 3:59:09 PM
July 2022 - Q2 2022 : India Investment Market Watch India By Savills India • With 4.1% growth in Q4 FY 2022, India’s overall GDP growth stood at 8.7% in FY 2022 against the contraction of 6.6% in FY 2021. • India recorded a highest-ever Foreign Direct Investment (FDI) of USD 83.57 billion in FY 2022. FDI equity inflow in the manufacturing sector increased by 76% YOY. • The Indian Rupee breached the 79 mark against the US Dollar for the first time on 28th June 2022. • Retail inflation, as measured by the Consumer Price Index (CPI), ...
July 2022 - Q2 2022 : India Investment Market Watch India By Savills India
July 2022 - Q2 2022 : India Investment Market Watch India By Savills India
Source: PR Agency
18/07/2022 2:53:00 PM